[go: up one dir, main page]

PE20070701A1 - Terapia contra el cancer con estrogeno - Google Patents

Terapia contra el cancer con estrogeno

Info

Publication number
PE20070701A1
PE20070701A1 PE2006001549A PE2006001549A PE20070701A1 PE 20070701 A1 PE20070701 A1 PE 20070701A1 PE 2006001549 A PE2006001549 A PE 2006001549A PE 2006001549 A PE2006001549 A PE 2006001549A PE 20070701 A1 PE20070701 A1 PE 20070701A1
Authority
PE
Peru
Prior art keywords
cancer
estrogen
postmenopausic
paclitaxel
against cancer
Prior art date
Application number
PE2006001549A
Other languages
English (en)
Inventor
Jack W Singer
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37891993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of PE20070701A1 publication Critical patent/PE20070701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO PARA EL CANCER QUE CONSISTE A) EN IDENTIFICAR UN PACIENTE CON CANCER QUE TIENE UN NIVEL DE ESTROGENO PREMENOPAUSICO EN PLASMA DE 30PG/ML Y POSTMENOPAUSICO; Y B) ADMINISTRAR UN CONJUGADO QUE COMPRENDE a) UN POLIMERO POLI(AMINOACIDO) TAL COMO POLI(ACIDO GLUTAMICO) CONJUGADO A b) UNA DROGA ANTI-CANCER TAL COMO PACLITAXEL, EL CUAL SE ADMINISTRA EN UNA CANTIDAD DE 175 A 250MG/M2 DE EQUIVALENTES DE PACLITAXEL; Y OPCIONALMENTE UNA TERAPIA CON ESTROGENO EN EL CASO DEL PACIENTE QUE TIENE UN NIVEL DE ESTROGENO POSTMENOPAUSICO. DICHO METODO DE TRATAMIENTO SE CARACTERIZA PORQUE EL CANCER PRESENTA CELULAS CANCERIGENAS QUE TIENEN RECEPTORES DE ESTROGENO O EL CANCER SE ORIGINO EN UN TEJIDO U ORGANO QUE TIENE CELULAS QUE POSEEN RECEPTORES DE ESTROGENO
PE2006001549A 2005-12-06 2006-12-05 Terapia contra el cancer con estrogeno PE20070701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74272505P 2005-12-06 2005-12-06
US81422106P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
PE20070701A1 true PE20070701A1 (es) 2007-07-20

Family

ID=37891993

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001549A PE20070701A1 (es) 2005-12-06 2006-12-05 Terapia contra el cancer con estrogeno

Country Status (9)

Country Link
US (1) US20070167349A1 (es)
EP (1) EP1957065A1 (es)
JP (1) JP2009518406A (es)
KR (1) KR20080074202A (es)
CA (1) CA2630553A1 (es)
PE (1) PE20070701A1 (es)
RU (1) RU2008127309A (es)
TW (1) TWI322010B (es)
WO (1) WO2007067498A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014250A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Prediction of cancer therapy based on cathespin b levels
WO2010014249A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Cancer therapy comprising estrogen inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB9120653D0 (en) * 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
IL126179A (en) * 1996-03-12 2003-04-10 Pg Txl Co Lp Pharmaceutical compositions containing anti-tumor drug conjugates
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CA2366697A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for hormone-sensitive cancers
MXPA02003719A (es) * 1999-10-12 2002-08-30 Cell Therapeutics Inc Fabricacion de congujados de poliglutamato-agente terapeutico.

Also Published As

Publication number Publication date
KR20080074202A (ko) 2008-08-12
EP1957065A1 (en) 2008-08-20
US20070167349A1 (en) 2007-07-19
WO2007067498A1 (en) 2007-06-14
TW200803836A (en) 2008-01-16
JP2009518406A (ja) 2009-05-07
TWI322010B (en) 2010-03-21
CA2630553A1 (en) 2007-06-14
RU2008127309A (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
WO2009105432A3 (en) Devices and methods for delivery of a therapeutic agent through a pneumostoma
BR112022014070A2 (pt) Nanopartículas de lipídio para dispensar medicamentos in vivo e usos das mesmas
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
MX2013010340A (es) Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
EP4458896A3 (en) Bioorthogonal compositions
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
UA105210C2 (ru) Противораковая вакцина и ее применение
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
WO2010009111A3 (en) A drug depot implantable within a synovial joint
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
IN2012DN00407A (es)
CY1123398T1 (el) Συνθεση συνδυασμου
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
ES2525066T3 (es) Uso terapéutico de preparaciones farmacéuticas que contienen fármacos antitumorales unidos a ácido hialurónico en el tratamiento de neoplasias
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
WO2014160216A3 (en) Dual targeting anticancer agents
ATE507818T1 (de) Orale verabreichung eines calcitonins

Legal Events

Date Code Title Description
FC Refusal